Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 4
2000 5
2001 13
2002 16
2003 20
2004 43
2005 49
2006 51
2007 58
2008 78
2009 88
2010 98
2011 96
2012 101
2013 100
2014 101
2015 107
2016 95
2017 87
2018 105
2019 123
2020 124
2021 119
2022 132
2023 126
2024 49

Text availability

Article attribute

Article type

Publication date

Search Results

1,747 results

Results by year

Filters applied: . Clear all
Page 1
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA. Limaye AP, et al. JAMA. 2023 Jul 3;330(1):33-42. doi: 10.1001/jama.2023.9106. JAMA. 2023. PMID: 37279999 Free PMC article.
Quantifiable CMV DNAemia was detected in 2.1% of participants in the letermovir group vs 8.8% in the valganciclovir group by week 28. Of participants evaluated for suspected CMV disease or CMV DNAemia, none (0/52) who received letermovir and 12.1% (8/66) who received va …
Quantifiable CMV DNAemia was detected in 2.1% of participants in the letermovir group vs 8.8% in the valganciclovir group by week 28. …
A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
Reischig T, Vlas T, Kacer M, Pivovarcikova K, Lysak D, Nemcova J, Drenko P, Machova J, Bouda M, Sedivcova M, Kormunda S. Reischig T, et al. J Am Soc Nephrol. 2023 May 1;34(5):920-934. doi: 10.1681/ASN.0000000000000090. Epub 2023 Feb 2. J Am Soc Nephrol. 2023. PMID: 36749127 Clinical Trial.
RESULTS: The incidence of acute rejection was lower with valganciclovir prophylaxis than with preemptive therapy (13%, 9/70 versus 23%, 16/70), but the difference was not statistically significant. ...CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Optimizing Valg …
RESULTS: The incidence of acute rejection was lower with valganciclovir prophylaxis than with preemptive therapy (13%, 9/70 versus 23 …
Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
Papanicolaou GA, Avery RK, Cordonnier C, Duarte RF, Haider S, Maertens J, Peggs KS, Solano C, Young JH, Fournier M, Murray RA, Wu J, Winston DJ; AURORA Trial Investigators. Papanicolaou GA, et al. Clin Infect Dis. 2024 Mar 20;78(3):562-572. doi: 10.1093/cid/ciad709. Clin Infect Dis. 2024. PMID: 38036487 Free PMC article. Clinical Trial.
BACKGROUND: Neutropenia may limit the use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). ...With maribavir (vs valganciclovir), fewer patients experienced neutropenia (16.1% and 52.9%) or discontinued d …
BACKGROUND: Neutropenia may limit the use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cel …
Valganciclovir: recent progress.
Pescovitz MD. Pescovitz MD. Am J Transplant. 2010 Jun;10(6):1359-64. doi: 10.1111/j.1600-6143.2010.03112.x. Epub 2010 Mar 28. Am J Transplant. 2010. PMID: 20455881 Free article. Review.
In 2001 valganciclovir was approved by the FDA for treatment of HIV associated retinitis and in 2003 for prevention of post transplant CMV. ...
In 2001 valganciclovir was approved by the FDA for treatment of HIV associated retinitis and in 2003 for prevention of post transplan …
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, Duarte RF, Florescu DF, Kamar N, Kumar D, Maertens J, Marty FM, Papanicolaou GA, Silveira FP, Witzke O, Wu J, Sundberg AK, Fournier M; SOLSTICE Trial Investigators. Avery RK, et al. Clin Infect Dis. 2022 Sep 10;75(4):690-701. doi: 10.1093/cid/ciab988. Clin Infect Dis. 2022. PMID: 34864943 Free PMC article. Clinical Trial.
METHODS: In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomized 2:1 to maribavir 400 mg twice daily or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for …
METHODS: In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomize …
Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.
Yu MA, Park JM. Yu MA, et al. Expert Opin Pharmacother. 2013 Apr;14(6):807-15. doi: 10.1517/14656566.2013.778244. Epub 2013 Mar 8. Expert Opin Pharmacother. 2013. PMID: 23469871 Review.
AREAS COVERED: This article examines the safety and efficacy of valganciclovir in pediatric SOT patients, with a particular focus on prophylaxis of CMV infections. ...Although comprehensive data are lacking, valganciclovir is a treatment option for CMV infection in …
AREAS COVERED: This article examines the safety and efficacy of valganciclovir in pediatric SOT patients, with a particular focus on …
New Perspectives on Antimicrobial Agents: Maribavir.
Halpern-Cohen V, Blumberg EA. Halpern-Cohen V, et al. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0240521. doi: 10.1128/aac.02405-21. Epub 2022 Aug 2. Antimicrob Agents Chemother. 2022. PMID: 35916518 Free PMC article. Review.
Food and Drug Administration in November 2021 for the treatment of adult and pediatric patients with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, …
Food and Drug Administration in November 2021 for the treatment of adult and pediatric patients with post-transplant cytomegalovirus (CMV) i …
CMV: Prevention, Diagnosis and Therapy.
Kotton CN. Kotton CN. Am J Transplant. 2013 Feb;13 Suppl 3:24-40; quiz 40. doi: 10.1111/ajt.12006. Am J Transplant. 2013. PMID: 23347212 Free article. Review.
Therapy primarily involves ganciclovir, now rendered more versatile by data suggesting oral therapy with valganciclovir is not inferior to intravenous therapy with ganciclovir. ...
Therapy primarily involves ganciclovir, now rendered more versatile by data suggesting oral therapy with valganciclovir is not inferi …
Valganciclovir and human herpesvirus-8.
Crumpacker CS. Crumpacker CS. J Infect Dis. 2008 Jul 1;198(1):6-7. doi: 10.1086/588821. J Infect Dis. 2008. PMID: 18491975 No abstract available.
1,747 results